Clinical trial
Chemotherapy for Participants With Lymphoma
NCT00436280 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00436280 |
|---|---|
| Title | Chemotherapy for Participants With Lymphoma |
| Official title | An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine and Oxaliplatin Plus Enzastaurin as Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Large Cell, Diffuse |
| Intervention type | Drug |
| Interventions | enzastaurin, gemcitabine, rituximab, oxaliplatin |
| Enrollment | 68 |
| Start date | Feb 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2012 |
| First posted | Feb 19, 2007 |
| Last update posted | Aug 6, 2020 |
| Countries | France, Germany, Russia |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: